Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Biogen Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Price to earnings (P/E) 13.75 14.62 20.78 20.79 25.33 25.36 12.95 10.02 8.14 7.50 8.11 9.97 9.43 8.40 9.32 14.79 19.99 25.30 18.66 28.83
Price to operating profit (P/OP) 11.75 10.63 12.16 11.39 20.36 21.96 10.53 8.81 6.21 6.03 6.48 8.34 7.58 6.74 7.43 11.13 10.78 12.80 9.45 13.70
Price to sales (P/S) 3.80 2.83 2.78 2.95 3.53 4.16 3.09 2.98 2.90 3.07 3.31 4.08 3.57 3.16 3.15 4.87 4.81 5.83 4.39 5.96
Price to book value (P/BV) 3.08 2.54 2.68 2.97 3.75 4.52 3.65 3.75 3.85 3.93 3.80 4.40 3.63 3.44 3.15 5.03 4.63 6.13 3.94 5.80 5.19 5.16 5.30

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Biogen Inc. P/E ratio decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Biogen Inc. P/OP ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 not reaching Q1 2022 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Biogen Inc. P/S ratio increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Biogen Inc. P/BV ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 exceeding Q1 2022 level.

Price to Earnings (P/E)

Biogen Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 144,001,404 145,113,047 146,452,013 146,962,793 146,892,712 149,033,443 150,554,750 152,335,731 153,881,597 158,313,471 163,187,486 174,064,011 180,441,878 184,447,218 193,893,397 196,708,784 201,482,595 201,442,850 211,007,945 211,562,686 211,476,936 211,431,746 212,115,203
Selected Financial Data (US$)
Net income attributable to Biogen Inc. (in thousands) 1,134,700 1,058,000 303,800 368,200 329,200 448,500 410,200 357,900 701,500 1,542,100 1,399,100 1,439,700 1,545,900 1,494,100 1,408,800 946,800 1,444,400 866,600 1,172,900 (297,400) 1,226,100 862,800 747,600
Earnings per share (EPS)2 19.89 14.19 9.90 10.59 10.52 12.87 20.00 26.26 33.03 37.44 36.02 33.83 29.90 28.70 24.07 22.52 15.82 14.73 14.05 12.00 0.00 0.00 0.00
Share price1, 3 273.56 207.49 205.70 220.17 266.57 326.36 259.00 263.25 268.91 280.81 292.25 337.24 281.87 241.24 224.40 333.24 316.15 372.84 262.15 346.00 315.73 282.96 286.89
Valuation Ratio
P/E ratio4 13.75 14.62 20.78 20.79 25.33 25.36 12.95 10.02 8.14 7.50 8.11 9.97 9.43 8.40 9.32 14.79 19.99 25.30 18.66 28.83
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82
Amgen Inc. 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07
Bristol-Myers Squibb Co. 23.71 24.14 25.64 20.92 144.77 41.99
Eli Lilly & Co. 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19
Gilead Sciences Inc. 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48 59.19 19.58 16.45
Johnson & Johnson 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99
Merck & Co. Inc. 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60
Pfizer Inc. 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63
Regeneron Pharmaceuticals Inc. 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86
Thermo Fisher Scientific Inc. 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36
Vertex Pharmaceuticals Inc. 24.62 23.12 26.50 26.55 22.09 26.26 20.45 20.18 20.14 34.05 43.74 52.90

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2022 Calculation
EPS = (Net income attributable to Biogen Inc.Q3 2022 + Net income attributable to Biogen Inc.Q2 2022 + Net income attributable to Biogen Inc.Q1 2022 + Net income attributable to Biogen Inc.Q4 2021) ÷ No. shares of common stock outstanding
= (1,134,700,000 + 1,058,000,000 + 303,800,000 + 368,200,000) ÷ 144,001,404 = 19.89

3 Closing price as at the filing date of Biogen Inc. Quarterly or Annual Report.

4 Q3 2022 Calculation
P/E ratio = Share price ÷ EPS
= 273.56 ÷ 19.89 = 13.75

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Biogen Inc. P/E ratio decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Price to Operating Profit (P/OP)

Biogen Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 144,001,404 145,113,047 146,452,013 146,962,793 146,892,712 149,033,443 150,554,750 152,335,731 153,881,597 158,313,471 163,187,486 174,064,011 180,441,878 184,447,218 193,893,397 196,708,784 201,482,595 201,442,850 211,007,945 211,562,686 211,476,936 211,431,746 212,115,203
Selected Financial Data (US$)
Income from operations (in thousands) 1,315,100 840,900 610,700 587,100 794,000 485,700 973,900 (330,700) 1,086,400 1,974,500 1,819,900 1,777,700 1,806,300 1,955,900 1,502,700 1,443,100 1,697,600 1,213,200 1,534,700 1,465,800 1,653,500 1,200,600 1,024,300
Operating profit per share2 23.29 19.52 16.92 19.33 13.09 14.86 24.60 29.87 43.27 46.61 45.10 40.46 37.18 35.78 30.21 29.94 29.34 29.13 27.75 25.26 0.00 0.00 0.00
Share price1, 3 273.56 207.49 205.70 220.17 266.57 326.36 259.00 263.25 268.91 280.81 292.25 337.24 281.87 241.24 224.40 333.24 316.15 372.84 262.15 346.00 315.73 282.96 286.89
Valuation Ratio
P/OP ratio4 11.75 10.63 12.16 11.39 20.36 21.96 10.53 8.81 6.21 6.03 6.48 8.34 7.58 6.74 7.43 11.13 10.78 12.80 9.45 13.70
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82
Amgen Inc. 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84
Bristol-Myers Squibb Co. 17.79 18.62 20.32 19.84 39.45 33.97 27.33 24.42
Eli Lilly & Co. 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08
Gilead Sciences Inc. 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38 29.86 21.83 20.66
Johnson & Johnson 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83
Merck & Co. Inc. 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47
Pfizer Inc. 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12 22.27 22.17 17.42 14.36
Regeneron Pharmaceuticals Inc. 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01
Thermo Fisher Scientific Inc. 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84
Vertex Pharmaceuticals Inc. 19.41 18.11 22.13 22.35 18.14 23.06 18.68 19.16 20.35 33.91 40.27 51.98

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2022 Calculation
Operating profit per share = (Income from operationsQ3 2022 + Income from operationsQ2 2022 + Income from operationsQ1 2022 + Income from operationsQ4 2021) ÷ No. shares of common stock outstanding
= (1,315,100,000 + 840,900,000 + 610,700,000 + 587,100,000) ÷ 144,001,404 = 23.29

3 Closing price as at the filing date of Biogen Inc. Quarterly or Annual Report.

4 Q3 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 273.56 ÷ 23.29 = 11.75

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Biogen Inc. P/OP ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 not reaching Q1 2022 level.

Price to Sales (P/S)

Biogen Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 144,001,404 145,113,047 146,452,013 146,962,793 146,892,712 149,033,443 150,554,750 152,335,731 153,881,597 158,313,471 163,187,486 174,064,011 180,441,878 184,447,218 193,893,397 196,708,784 201,482,595 201,442,850 211,007,945 211,562,686 211,476,936 211,431,746 212,115,203
Selected Financial Data (US$)
Revenue (in thousands) 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Sales per share2 71.97 73.28 73.88 74.72 75.57 78.49 83.72 88.26 92.69 91.51 88.38 82.60 78.88 76.29 71.23 68.39 65.68 63.90 59.69 58.02 0.00 0.00 0.00
Share price1, 3 273.56 207.49 205.70 220.17 266.57 326.36 259.00 263.25 268.91 280.81 292.25 337.24 281.87 241.24 224.40 333.24 316.15 372.84 262.15 346.00 315.73 282.96 286.89
Valuation Ratio
P/S ratio4 3.80 2.83 2.78 2.95 3.53 4.16 3.09 2.98 2.90 3.07 3.31 4.08 3.57 3.16 3.15 4.87 4.81 5.83 4.39 5.96
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22
Amgen Inc. 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03
Bristol-Myers Squibb Co. 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16 3.66 3.97 4.45 5.52
Eli Lilly & Co. 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03
Gilead Sciences Inc. 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24 3.29 3.95 4.34 4.00
Johnson & Johnson 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79
Merck & Co. Inc. 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33
Pfizer Inc. 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50 4.71 4.69 4.21 3.66
Regeneron Pharmaceuticals Inc. 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34
Thermo Fisher Scientific Inc. 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83
Vertex Pharmaceuticals Inc. 9.26 8.85 8.17 8.21 6.74 7.82 8.81 8.82 9.04 13.11 13.71 14.95

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2022 Calculation
Sales per share = (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021) ÷ No. shares of common stock outstanding
= (2,508,500,000 + 2,589,100,000 + 2,531,800,000 + 2,733,800,000) ÷ 144,001,404 = 71.97

3 Closing price as at the filing date of Biogen Inc. Quarterly or Annual Report.

4 Q3 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 273.56 ÷ 71.97 = 3.80

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Biogen Inc. P/S ratio increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Price to Book Value (P/BV)

Biogen Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 144,001,404 145,113,047 146,452,013 146,962,793 146,892,712 149,033,443 150,554,750 152,335,731 153,881,597 158,313,471 163,187,486 174,064,011 180,441,878 184,447,218 193,893,397 196,708,784 201,482,595 201,442,850 211,007,945 211,562,686 211,476,936 211,431,746 212,115,203
Selected Financial Data (US$)
Total Biogen Inc. shareholders’ equity (in thousands) 12,775,500 11,872,500 11,242,300 10,896,200 10,429,900 10,751,900 10,682,200 10,700,300 10,758,500 11,308,700 12,546,900 13,343,200 13,995,900 12,952,900 13,829,900 13,039,600 13,766,600 12,260,900 14,053,700 12,612,800 12,860,500 11,585,200 11,479,000
Book value per share (BVPS)2 88.72 81.82 76.76 74.14 71.00 72.14 70.95 70.24 69.91 71.43 76.89 76.66 77.56 70.23 71.33 66.29 68.33 60.87 66.60 59.62 60.81 54.79 54.12
Share price1, 3 273.56 207.49 205.70 220.17 266.57 326.36 259.00 263.25 268.91 280.81 292.25 337.24 281.87 241.24 224.40 333.24 316.15 372.84 262.15 346.00 315.73 282.96 286.89
Valuation Ratio
P/BV ratio4 3.08 2.54 2.68 2.97 3.75 4.52 3.65 3.75 3.85 3.93 3.80 4.40 3.63 3.44 3.15 5.03 4.63 6.13 3.94 5.80 5.19 5.16 5.30
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31
Amgen Inc. 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92
Bristol-Myers Squibb Co. 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91
Eli Lilly & Co. 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37
Gilead Sciences Inc. 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83
Johnson & Johnson 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39
Merck & Co. Inc. 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31
Pfizer Inc. 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84
Regeneron Pharmaceuticals Inc. 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74
Thermo Fisher Scientific Inc. 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02
Vertex Pharmaceuticals Inc. 6.18 6.19 5.95 6.16 5.04 5.69 6.29 6.30 6.66 9.42 10.23 10.23 9.57 9.09 9.36

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2022 Calculation
BVPS = Total Biogen Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 12,775,500,000 ÷ 144,001,404 = 88.72

3 Closing price as at the filing date of Biogen Inc. Quarterly or Annual Report.

4 Q3 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 273.56 ÷ 88.72 = 3.08

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Biogen Inc. P/BV ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 exceeding Q1 2022 level.